How to Buy Sage Therapeutics Stock
Sage Therapeutics Inc
Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders.
Sage Therapeutics stock last closed at $19.27, up 0.84% from the previous day, and has decreased 49.18% in one year. It has underperformed other stocks in the Biotechnology industry by 0.21 percentage points. Sage Therapeutics stock is currently +16.68% from its 52-week low of $16.52, and -67.88% from its 52-week high of $59.99.
There are currently 59.97M shares of SAGE outstanding. The market capitalization of SAGE is $1.16B. In the past 24 hours, 746,131 SAGE shares were traded.
How to Buy Sage Therapeutics Stock
Not sure how to invest in Sage Therapeutics stock? Here's how.
- Figure out where to buy Sage Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Sage Therapeutics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your payment method and add your details.
- Analyze Sage Therapeutics stock: The Sage Therapeutics ticker symbol is SAGE. Is Sage Therapeutics stock a good investment? Should you buy shares of SAGE? How do SAGE's underlying business fundamentals look? Do top analysts think Sage Therapeutics is a good buy? Why has SAGE's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if SAGE is a good stock to buy).
- Place your SAGE purchase: Decide if you will purchase SAGE shares at the current market price or use a limit order to buy SAGE stock at a particular price.
- Get updates on your investment in SAGE: Create a watchlist to track your position in Sage Therapeutics stock.
Step 1: Figure out where to buy Sage Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy SAGE shares.
Our recommended brokerage: eToro
Based on our experience, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global financial markets: From Tech to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal info so you are able to buy SAGE stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to create your new brokerage account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've finished signing up on the best free stock trading app, you need to deposit funds:
Check out the tutorial below for more details depositing money into your new brokerage account.
Step 4: Analyze Sage Therapeutics stock
After you have chosen the best place to buy Sage Therapeutics stock, it's absolutely critical to analyze their stock before you buy, so you truly comprehend the risk as well as the opportunity.
Sage Therapeutics Metrics
Sage Therapeutics Fundamentals
WallStreetZen was created to help average investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on SAGE's stock page.
Is SAGE stock undervalued or overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge SAGE's true value.
Using relative valuations metrics:
- SAGE may be undervalued based on its P/B ratio of 1.42x, relative to Biotechnology industry P/B ratio of 5.31x
You can access additional valuation research on SAGE's stock here.
A look at SAGE Cashflows and Balance Sheet
Pros:
- There are more short-term assets than short-term liabilities on the SAGE balance sheet.
- SAGE has $877.38M in cash and short term investments. This is sufficient to cover its annual cash burn of $548.95M.
- SAGE has cash burn of 548945000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the SAGE balance sheet.
- SAGE has a low debt to equity ratio of 0.16.
Cons:
- SAGE profit margin has gone up by 21.16 percentage points in the past year, but the company is still unprofitable.
- Total SAGE debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy SAGE stock, according to analysts?
Out of 14 Equities analysts who track SAGE, the consensus analyst rating on Sage Therapeutics is a Hold
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest SAGE Analyst Ratings
Vikram Purohit, a bottom 8% analyst from Morgan Stanley maintains SAGE with a hold rating and lowers their SAGE price target from $49.00 to $20.00, on Aug 9, 2023.
Ritu Baral, a bottom 2% analyst from TD Cowen maintains SAGE with a buy rating and lowers their SAGE price target from $105.00 to $28.00, on Aug 8, 2023.
Jay Olson, a top 7% analyst from Oppenheimer maintains SAGE with a hold rating and lowers their SAGE price target from $24.00 to $20.00, on Aug 8, 2023.
Joon Lee, a bottom 34% analyst from Truist Securities maintains SAGE with a hold rating and lowers their SAGE price target from $40.00 to $20.00, on Aug 8, 2023.
Sumant Kulkarni, a bottom 8% analyst from Canaccord Genuity downgrades SAGE to a hold rating and lowers their SAGE price target from $64.00 to $21.00, on Aug 8, 2023.
Canaccord Genuity's Sumant Kulkarni downgraded their rating on Sage Therapeutics (NASDAQ: SAGE) from Strong Buy to Hold on 2023/08/08. The analyst also lowered their price target by 67.2% from $64 to $21.
In a note published following the release of the company's Q2 2023 print on 2023/08/07, the analyst said he made the moves to reflect the FDA's rejection of zuranolone for the treatment of major depressive disorder* (MDD) and "uncertainty resulting from this outcome."
"Fresh from this unfortunate outcome," management did not provide many details on a path forward in MDD during the earnings call other than to appeal the rejection using conventional channels, Kulkarni reported.
Looking ahead, besides zuranolone clinical-trial-related data, other catalysts are "some time off," the analyst noted.
Footnotes
* In an announcement on 2023/08/04, the FDA approved zuranolone for adults with postpartum depression (PPD) but denied it in the treatment of adults with major depressive disorder (MDD).
Earnings Report
On 2023/08/07, Sage Therapeutics reported:
- Loss per share of $2.68, which missed the Zacks Consensus Estimate of $(2.53) and, by 25.8%, Q2 2022's loss of $2.13.
- Revenue of $2.47M, which missed the Zacks Consensus Estimate by 15.19% but beat Q2 2022's $1.5M by 64.7%.
Management guided:
- Current cash, cash equivalents and marketable securities, along with anticipated funding from ongoing collaborations and potential revenue, will support operations into 2025.
- Ongoing resource allocation evaluation, including pipeline prioritization and a workforce reorganization, with a goal of extending its cash runway and anticipates operating expenses will decrease in 2024.
- A potential milestone payment of $75M from Biogen related to the first commercial sale of ZURZUVAE for the treatment of PPD (postpartum depression).
CEO Barry Greene commented: “We are currently at a tipping point with the burden and prevalence of brain health conditions accelerating at an alarming rate. The need has never been greater than it is today and our team is singularly focused on changing the trajectory of these devastating diseases through our development efforts and novel pipeline.
“We were delighted to receive U.S. Food and Drug Administration (FDA) approval for ZURZUVAE as the first-and-only oral treatment specifically indicated for adults with postpartum depression (PPD), the most common medical complication of childbirth. We believe the need for new treatment options for women with PPD is a significant medical need and presents a strong business opportunity.
"While we were very disappointed by the recent Complete Response Letter (CRL) we received from the FDA regarding zuranolone in the treatment of major depressive disorder (MDD), we are reviewing the feedback from the FDA and evaluating our next steps.”
“While we believe we are well capitalized, given the impact of the CRL for zuranolone in MDD on our plans, we are currently evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.
"With a right-sized organization and portfolio, we believe we have an opportunity to emerge as an even stronger company. We plan to provide greater detail and next steps before the end of Q3."
You can dig deeper into what analysts are saying on the Sage Therapeutics stock forecast page.
SAGE Technicals
SAGE Performance Numbers
Last year, SAGE revenue was $11.35M. In the last five year, SAGE's revenue has grown by -33.91% per year. This was slower than the Biotechnology industry average of 35.68%.
Find out more about SAGE's earnings and revenue performance here.
Who is buying/selling SAGE?
Over the last 12 months, executives and large shareholders at SAGE have bought more shares than they have sold.
Elizabeth Barrett, Director of SAGE, was the latest SAGE insider to buy. They bought $37,278.00 worth of SAGE stock on Aug 9, 2023.
Dig into more about who owns SAGE stock here.
Does SAGE stock generate passive income?
No, Sage Therapeutics doesn't provide an income stream by paying out dividends.
SAGE Social Trading Data
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your SAGE purchase
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a specific dollar amount, use a limit order.
Press the Open Trade button and your broker will place your order.
If you want more help buying stocks on eToro, click the how to video below:
Step 6: Get updates on your investment in SAGE
Now that you own some SAGE shares, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to track your SAGE stock.
SAGE Feed
How to Buy Stock in Sage Therapeutics
To summarize, here are the 6 steps to buy stock in Sage Therapeutics:
- Figure out where to buy Sage Therapeutics stock
- Sign up for your brokerage account
- Fund your brokerage account
- Analyze Sage Therapeutics stock
- Place your SAGE purchase
- Get updates on your investment in SAGE
If you need a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep track of your new investment in Sage Therapeutics, create your watchlist below.
More Articles You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.